archive-com.com » COM » A » AGENDIA.COM

Total: 235

Choose link from "Titles, links and description words view":

Or switch to "Titles and links view".
  • Agendia Appoints Dr. Stefan Glück to Chair Medical Advisory Board | Agendia
    Director Southern Alberta Breast Cancer Program at the Tom Baker Cancer Center and a Professor in the departments of oncology medicine pharmacology and therapeutics at the University of Calgary in Alberta Canada and Deputy Head Department of Oncology at the University of Calgary Dr Glück brings over 20 years of clinical experience in the medical profession to Agendia s Medical Advisory Board said David Macdonald CEO of Agendia Agendia is committed to advancing the future of personalized medicine through the development of new diagnostic tests Dr Glück s extensive knowledge and vast experience will provide our Medical Advisory Board with strong leadership as we continue to bring Agendia s rich product pipeline to market Dr Glück was presented the America s Top Oncologists award from Consumers Research Council of America He was also recognized as one of the Best Doctors in America from 2006 through 2012 He has authored or co authored more than 200 articles In addition Dr Glück has written or co written a number of book chapters and numerous journal abstracts and he has presented more than 350 papers at national and international meetings Dr Glück completed his medical studies at the Free University of West Berlin Germany The internship in Berlin was followed by residency in internal medicine and fellowship in hematology at the Heinrich Heine Universität in Düsseldorf Germany and a medical oncology and bone marrow transplant fellowship at the Princess Margaret Hospital University of Toronto in Canada About Agendia Agendia is a leading molecular diagnostic company that develops and markets genomic based diagnostic products which help support physicians with their complex treatment decisions Agendia s breast cancer Symphony suite was developed using unbiased gene selection analyzing the complete human genome ensuring 100 definitive results for cancer patients Symphony includes MammaPrint the first and only

    Original URL path: http://www.agendia.com/agendia-appoints-dr-stefan-gluck-to-chair-medical-advisory-board-2/ (2016-05-01)
    Open archived version from archive


  • Agendia Welcomes Dr. Mark Gittleman to Expanding Medical Advisory Board | Agendia
    join Agendia s Medical Advisory Board and I look forward to contributing and sharing new ideas to reach our common goals As a breast cancer specialist Dr Gittleman has a vested interest in new technologies that enable medical professionals to better understand the biology of breast cancer thereby helping patients attain better outcomes through the application of validated clinically useful technologies such as Agendia s MammaPrint BluePrint TargetPrint and TheraPrint gene profiling tests He is a past president of the American Society of Breast Surgeons Dr Gittleman currently serves on the ASBS Coding and Reimbursement and Breast Imaging Technology committees and is a reviewer for Ultrasound and Stereotactic certification applicants With his vast knowledge and experience in breast imaging and minimally invasive biopsy techniques Dr Gittleman brings a unique perspective to our growing Medical Advisory Board said David Macdonald CEO of Agendia As Agendia invests significantly in clinical research studies to support the use of new diagnostic tests our Medical Advisory Board will be an integral part of our clinical trial development We look forward to working with Dr Gittleman in our efforts to advance the future of healthcare and bring personalized medicine to breast and colon cancer patients About Agendia Agendia is a leading molecular diagnostic company that develops and markets genomic based diagnostic products which help support physicians with their complex treatment decisions Agendia s breast cancer Symphony suite was developed using unbiased gene selection analyzing the complete human genome ensuring 100 definitive results for cancer patients Symphony includes MammaPrint the first and only FDA cleared IVDMIA breast cancer recurrence assay as well as BluePrint a molecular subtyping assay TargetPrint an ER PR HER2 expression assay and TheraPrint an alternative therapy selection assay Together these tests help physicians determine a patient s individual risk for metastasis which patients

    Original URL path: http://www.agendia.com/agendia-welcomes-dr-mark-gittleman-to-expanding-medical-advisory-board/ (2016-05-01)
    Open archived version from archive

  • Agendia Names Industry Veteran Glen Fredenberg CFO and Vice President of Finance | Agendia
    with financial management and corporate governance primarily in the clinical laboratory industry Previously Fredenberg was the CFO at US Labs in Irvine California which grew from 1 million in revenue to more than 80 million in revenue and was then successfully sold to LabCorp in 2005 Most recently he has been the CFO at Clarient in Aliso Viejo California which has grown to 140 million in revenue and was successfully sold to GE Healthcare in late 2010 Fredenberg holds a Bachelor of Science in Business Administration from California State University Fullerton and is a licensed Certified Public Accountant The addition of Glen Fredenberg to our executive team will have a tremendous impact on Agendia and will accelerate our progress in the molecular diagnostics industry said David Macdonald CEO of Agendia Our team is focused on the commercialization of our current breast and colon cancer Symphony suite of tests as well as the development of our personalized medicine pipeline About Agendia Agendia is a leading molecular diagnostic company that develops and markets genomic based diagnostic products which help support physicians with their complex treatment decisions Agendia s breast cancer Symphony suite was developed using unbiased gene selection analyzing the complete human genome ensuring 100 definitive results for cancer patients Symphony includes MammaPrint the first and only FDA cleared IVDMIA breast cancer recurrence assay as well as BluePrint a molecular subtyping assay TargetPrint an ER PR HER2 expression assay and TheraPrint an alternative therapy selection assay Together these tests help physicians determine a patient s individual risk for metastasis which patients will benefit from chemo hormonal or combination therapy and which patients do not require these treatments and can instead be treated with other less arduous and less costly methods In addition to the Symphony suite of tests Agendia has a rich

    Original URL path: http://www.agendia.com/agendia-names-industry-veteran-glen-fredenberg-cfo-and-vice-president-of-finance/ (2016-05-01)
    Open archived version from archive

  • Agendia Announces Launch of ColoPrint for Colon Cancer Prognosis and Prediction | Agendia
    choose treatment plans for colon cancer patients that are customized for each patient s individual needs said David Macdonald Agendia CEO We expect ColoPrint to be well received amongst physicians and patients for a more personalized management of this disease Colon cancer is the third most common cancer in men and women worldwide As with most cancers the stage at which colon cancer is diagnosed is a key factor in determining long term survival outcomes A key challenge in colon cancer management is determining the risk of relapse for patients with stage II colon cancer and deciding if these patients should receive adjuvant treatment such as radiotherapy or chemotherapy Surgery alone typically cures 80 percent of stage II colon cancer patients and identifying which patients will benefit from chemotherapy remains a challenge Today approximately 30 50 percent of stage II colon cancer patients receive adjuvant chemotherapy in the U S However due to the fact that the benefit of chemotherapy is small and its use is controversial the number of patients receiving adjuvant chemotherapy varies significantly from physician to physician and hospital to hospital There are few reliable clinical factors to identify patients who are more likely to benefit from adjuvant treatment and now ColoPrint provides a definitive risk stratification for every stage II colon cancer patient About Agendia Agendia is a leading molecular diagnostic company that develops and markets genomic based diagnostic products which help support physicians with their complex treatment decisions Agendia s breast cancer Symphony suite was developed using unbiased gene selection analyzing the complete human genome ensuring 100 definitive results for cancer patients Symphony includes MammaPrint the first and only FDA cleared IVDMIA breast cancer recurrence assay as well as BluePrint a molecular subtyping assay TargetPrint an ER PR HER2 expression assay and TheraPrint an alternative

    Original URL path: http://www.agendia.com/agendia-announces-launch-of-coloprint-for-colon-cancer-prognosis-and-prediction/ (2016-05-01)
    Open archived version from archive

  • News and Press Releases | Agendia - Part 11
    Nine Studies in Breast and Colon Cancer for Presentation at 2012 Annual Meeting of the American Society of Clinical Oncology ASCO 05 29 2012 AMSTERDAM THE NETHERLANDS and IRVINE CA May 29 2012 Agendia an innovative molecular cancer diagnostics company and leader in personalized medicine announced today that it will present nine posters on genomic research studies in breast and colon cancer at Continued RASTER First Ever Prospective Diagnostic Study in Breast Cancer 03 22 2012 RASTER Five Year Follow Up Data Indicates Chemotherapy May Be Safely Withheld for Patients Deemed Low Risk for Breast Cancer Recurrence Using Agendia s MammaPrint Test Data Presented at European Breast Cancer Conference IRVINE CA and AMSTERDAM THE NETHERLANDS March 22 2012 Continued Agendia Wins 2011 Scrip Award for Best Partnership Alliance 02 29 2012 IRVINE CA and AMSTERDAM THE NETHERLANDS FEBRUARY 29 2012 Agendia an innovative molecular cancer diagnostics company today announced that the company is a recipient of the 2011 Scrip Award for Best Partnership for its cooperative alliance between Agendia AstraZeneca Continued Agendia Presents Broad Array of Predictive and Prognostic Studies on Breast and Colorectal Cancers at ASCO 2010 Annual Meeting 06 04 2010 HUNTINGTON BEACH CA and AMSTERDAM THE NETHERLANDS

    Original URL path: http://www.agendia.com/agendia-news-and-press-releases/page/11/ (2016-05-01)
    Open archived version from archive

  • Agendia Raises $65 Million in a Private Round of Equity Financing | Agendia
    other new investors for the financing round including Korys the investment structure of the Colruyt family and others Debiopharm has been very impressed by the quality of the work and recent substantial progress made by Agendia to overcome the hurdles it faced in the past Agendia pioneered and advocated the implementation of personalized cancer management strategies Its offering both commercially and scientifically has advanced molecular cancer diagnosis in its growing role Becoming successful in this still challenging area will lead to substantial improvements for the selection of cancer therapies and therefore also enhance the cost effectiveness of highly innovative and valuable treatments for subsets of patients In other words to us Agendia will support genuine win win strategies and facilitate the reduction of the gap between the diagnostic and the drug world said Thierry Mauvernay Delegate of the Board of Debiopharm We are absolutely delighted to bring Agendia into our investment portfolio stated Vincent Vliebergh CEO of Korys The company s molecular diagnostic tests for breast cancer developed and validated in close collaboration with leading academic centers enable physicians to determine the most effective treatment for each individual patient leading to better health outcomes and lower costs As such we see Agendia as a catalyst in the shift to more personalized medicine and we look forward to working with the company to make this vision come true About Agendia Agendia is a leading molecular diagnostic company that develops and markets genomic based diagnostic products which help support physicians with their complex treatment decisions Agendia s breast cancer Symphony suite was developed using unbiased gene selection analyzing the complete human genome ensuring 100 definitive results for cancer patients Symphony includes MammaPrint the first and only FDA cleared IVDMIA breast cancer recurrence assay as well as BluePrint a molecular subtyping assay TargetPrint

    Original URL path: http://www.agendia.com/agendia-raises-65-million-in-a-private-round-of-equity-financing/ (2016-05-01)
    Open archived version from archive

  • Agendia Announces Nine Studies in Breast and Colon Cancer for Presentation at 2012 Annual Meeting of the American Society of Clinical Oncology (ASCO) | Agendia
    Theater Saturday June 2 2012 Breast Cancer 2 Poster Presentation Molecular subtyping using MammaPrint and BluePrint as an outcome predictor in 180 U S breast cancer BC patients Lead Author L Stork Sloots K Yao M Turk K Kaul J Weaver F De Snoo M Cristofanilli Presentation Time 8 00 AM 12 00 PM Location S Hall A2 Monday June 4 2012 Breast Cancer 3 Poster Presentation Discussion Comparison of molecular BluePrint MammaPrint and pathological subtypes for breast cancer among the first 800 patients from the EORTC 10041 BIG 3 04 MINDACT trial Lead Author G Viale L Slaets F De Snoo L J van t Veer E J Rutgers M J Piccart Gebhart J Bogaerts J van den Akker K Engelen L Russo P Dell Orto F Cardoso Presentation Time 1 15 PM 5 15 PM Location E450b Discussion Time 4 45 PM 5 45 PM Location N Hall B1 4 Poster Presentation Response and long term outcomes after neoadjuvant chemotherapy Pooled dataset of patients stratified by molecular subtyping by MammaPrint and BluePrint Lead Author S Gluck F De Snoo J Peeters G Somlo L van t Veer Presentation Time 1 15 PM 5 15 PM Location S Hall A2 5 Poster Presentation Central review of discordant samples for microarray based on ER PR and HER2 and local IHC FISH assessment worldwide from 827 patients Lead Author J Wesseling C Tinterri A Sapino F Zanconati M Lutke Holzik B Nguyen K B Deck P Querzoli T Perin C Giardina G Seitz J Guinebretiere J M Barone T Watanabe F De Snoo L Stork Sloots P Cusumano Presentation Time 1 15 PM 5 15 PM Location S Hall A2 6 Poster Presentation High concordance for MammaPrint 70 genes by RNA next generation sequencing Lead Author L Mittempergher I de Rink M Nieuwland R M Kerkhoven A Glas R Bernards L van t Veer Presentation Time 8 00 AM 12 00 PM Location S Hall A2 7 Poster Presentation Correlation between miRNA miR and gene expression profiles GEP and response to neoadjuvant chemotherapy NCT in patients with locally advanced and inflammatory breast cancer BC Lead Author S M Li X Wu P H Frankel H Gao G Sun F De Snoo J Rossi E Wang P Roepman Y Yen J Peeters L Stork G Somlo Presentation Time 1 15 PM 5 15 PM Location S Hall A2 Colorectal Cancer 8 Poster Presentation The PARSC trial a prospective study for the assessment of recurrence risk in stage II colon cancer patients using ColoPrint Lead Author R Salazar J Marshall J Capdevila B Glimelius J de Waard J Van Der Hoeven J Klaase F Bibeau T Bachleitner Hofmann R A Midgley E A Levine W L Law M Asano G J Chang S M Cohen R W Beart P M Goldfarb M McCarter L Stork Sloots R Rosenberg Presentation Time 1 15 PM 5 15 PM Location S Hall A2 Abstract Publication Breast Cancer 9 Abstract Publication Gene expression panel TheraPrint analyzed as

    Original URL path: http://www.agendia.com/agendia-announces-nine-studies-in-breast-and-colon-cancer-for-presentation-at-2012-annual-meeting-of-the-american-society-of-clinical-oncology-asco/ (2016-05-01)
    Open archived version from archive

  • RASTER: First-Ever Prospective Diagnostic Study in Breast Cancer | Agendia
    breast cancer recurrence via the MammaPrint assay and the five year distant metastasis free survival DMFS rate for those patients was 96 1 percent For patients deemed High Risk for breast cancer recurrence the five year DMFS rate was 89 8 percent whereby the vast majority of these patients received chemotherapy The data suggests that it is safe to withhold chemotherapy in low risk patient groups The excellent five year clinical outcome results for both low and high risk patients confirms the ability of MammaPrint to accurately stratify patients into appropriate treatment therapies The five year data from this prospective study clearly shows the promise of personalized medicine said David Macdonald CEO of Agendia In an era of rising health care costs MammaPrint informs physicians and patients as to the most effective course of treatment reducing unnecessary costs and improving patient outcomes About MammaPrint MammaPrint is the first and only breast cancer recurrence test cleared by the U S Food and Drug Administration FDA FDA clearance requires clinical and analytical validation and reporting systems to ensure patient safety issues are addressed Highly accurate MammaPrint identifies patients with early metastasis risk patients who are likely to develop metastases within five years following surgery Several authoritative studies have shown that chemotherapy particularly reduces early metastasis risk In planning treatment the MammaPrint test results provide doctors with a clear rationale to assess the benefit of chemotherapy in addition to other clinical information and pathology tests All MammaPrint tests are conducted in Agendia s CAP accredited FDA compliant and CLIA certified service laboratories About Agendia Agendia is a leading molecular diagnostic company that develops and markets genomic based diagnostic products that improve the quality of life for cancer patients and simplifies complex treatment decisions for their physicians Agendia s Symphony suite of breast cancer

    Original URL path: http://www.agendia.com/first-ever-prospective-diagnostic-study-in-breast-cancer/ (2016-05-01)
    Open archived version from archive



  •